Supplementary




Figure S1 Patient flow chart.

Treatment patterns	Responders/patier	
Camrelizumab only	12/37	· · · · · · · · · · · · · · · · · · ·
Camrelizumab plus chemotherapy	81/228	
Camreliuzmab plus others	23/85	
Treatment line		
First line	63/115	
Second line	38/140	
Third or later line	15/95	
Sex		
Female	18/87	
Male	98/263	i i i i i i i i i i i i i i i i i i i
Age		
<70 years	75/240	F-0-1
≥70 years	41/110	
Smokers		
No	35/123	
Yes	25/69	
ECOG PS	20.07	
0-1	101/308	
≥ 2	15/42	
Clinical stage	15/42	
III	25/68	
IV	91/282	
Histology	717202	
Non-squamous cell carcinoma	63/229	
Squamous cell carcinoma	51/116	
Liver metastasis	51/110	
No	103/309	
Yes	13/41	
Brain metastasis	15/41	
No	103/296	
Yes	13/54	
Adrenal metastasis	13/34	
No	88/267	
Yes	88/26/ 6/21	
PD-L1 expression	0/21	
<1%	(142	(
>1%	6/42	
EGFR/ALK mutation	23/47	
Negative	20.02	
Positive	28/82	
1.030000	17/64	

Figure S2 Subgroup analysis of ORR. ORR, overall response rate. CI, confidential interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase.




Figure S3 The ORR and DCR analysis with respect to camrelizumab treatment line and treatment patterns. ORR, overall response rate; DCR, disease control rate.

Voriables	Univariate analysis		Multivariate analysis		
Variables	HR (95%CI)	Р	HR (95%CI)	Р	
Age					
<70 years	Ref.		Ref.		
≥70 years	0.887 (0.641–1.226)	0.466	1.218 (0.862–1.722)	0.264	
Sex					
Female	Ref.		Ref.		
Male	1.235 (0.876–1.743)	0.229	0.924 (0.632–1.352)	0.685	
Smoking history					
No	Ref.		Ref.		
Yes	0.722 (0.454–1.148)	0.169	0.735 (0.452–1.195)	0.215	
ECOG performance status					
0–1	Ref.		Ref.		
≥2	1.004 (0.659–1.531)	0.984	0.898 (0.582–1.384)	0.625	
Histology					
Squamous cell carcinoma	Ref.		Ref.		
Non-squamous cell carcinoma	0.959 (0.693–1.328)	0.803	1.005 (0.344–2.936)	0.993	
Unspecified	1.321 (0.478–3.649)	0.592	1.152 (0.405–3.267)	0.790	
Clinical stage					
III	Ref.		Ref.		
IV	0.661 (0.425–1.029)	0.067	1.489 (0.927–2.391)	0.100	
Brain metastatic					
No	Ref.		Ref.		
Yes	1.108 (0.681–1.522)	0.930	0.926 (0.600–1.429)	0.728	
Liver metastatic					
No	Ref.		Ref.		
Yes	0.806 (0.514–1.264)	0.348	1.169 (0.733–1.862)	0.512	
Adrenal gland metastatic					
No	Ref.		Ref.		
Yes	0.935 (0.475–1.838)	0.845	0.985 (0.487–1.993)	0.966	
Treatment line					
First line	Ref		REF.		
Second line	1.168 (0.797–1.711)	0.426	1.189 (0.792–1.786)	0.403	
Third or later line	1.375 (0.923–2.048)	0.118	1.328 (0.857–2.058)	0.204	
Treatment patterns					
Camrelizumab monotherapy	Ref.		Ref.		
Camrelizumab plus chemotherapy	1.664 (0.915–3.024)	0.095	1.669 (0.899–3.098)	0.105	
Camrelizumab plus others*	1.821 (0.961–3.452)	0.066	1.762 (0.903–3.439)	0.097	

Table S1 Univariate and multivariate COX regression analysis of PFS

*, others including anti-angiogenesis therapy or plus chemotherapy, or targeted therapy. PFS, progression-free survival; HR, hazard ratio; CI, confidential interval; REF., reference; ECOG, Eastern Cooperative Oncology Group.

Variables	Univariate analysis		Multivariate analysis	
Variables	HR (95% CI)	Р	HR (95% CI)	Р
Age				
<70 years	Ref.		Ref.	
≥70 years	1.072 (0.669–1.719)	0.772	0.908 (0.549–1.502)	0.708
Sex				
Female	Ref.		Ref.	
Male	0.953 (0.570–1.592)	0.854	1.337 (0.767–2.331)	0.306
Smoking history				
No	Ref.		Ref.	
Yes	0.929 (0.504–1.713)	0.814	0.849 (0.448–1.609)	0.615
ECOG performance status				
0–1	Ref.		Ref.	
≥2	0.957 (0.534–1.715)	0.882	0.919 (0.504–1.674)	0.783
Histology				
Squamous cell carcinoma	Ref.		Ref.	
Non-squamous cell carcinoma	0.752 (0.482–1.172)	0.208	0.559 (0.338–0.924)	0.023
Unspecified	0.541 (0.074–3.964)	0.545	0.392 (0.050–3.057)	0.371
Clinical stage				
Ш	Ref.		Ref.	
IV	0.550 (0.283–1.067)	0.077	1.753 (0.866–3.548)	0.119
Brain metastases				
No	Ref.		Ref.	
Yes	0.871 (0.504–1.506)	0.622	1.152 (0.636–2.089)	0.641
Liver metastases				
No	Ref.		Ref.	
Yes	0.679 (0.368–1.254)	0.217	1.374 (0.730–2.587)	0.325
Adrenal gland metastases				
No	Ref.		Ref.	
Yes	0.530 (0.243–1.155)	0.110	0.798 (0.278–2.294)	0.676
Treatment line				
First line	Ref.		Ref.	
Second line	1.575 (0.879–2.823)	0.127	1.981 (1.072–3.662)	0.029
Third or later line	1.995 (1.102–3.613)	0.023	2.481 (1.285–4.790)	0.007
Treatment pattern				
Camrelizumab monotherapy	Ref.		Ref.	
Camrelizumab plus chemotherapy	1.326 (0.602–2.923)	0.484	1.326 (0.585–3.003)	0.499
Camrelizumab plus others*	1.566 (0.671–3.655)	0.300	1.564 (0.642–3.807)	0.325

Table S2 Univariate and multivariate COX regression analysis of OS

*, others including anti-angiogenesis therapy or plus chemotherapy, or targeted therapy. OS, overall survival; HR, hazard ratio; CI, confidential interval; REF., reference; ECOG, Eastern Cooperative Oncology Group.